Back to top
more

Illumina (ILMN)

(Delayed Data from NSDQ)

$117.61 USD

117.61
1,243,017

+3.12 (2.73%)

Updated Jul 22, 2024 04:00 PM ET

After-Market: $117.69 +0.08 (0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Illumina (ILMN) Q1 Earnings Beat Estimates, Margins Contract

by Zacks Equity Research

Illumina's (ILMN) Q1 revenues decline year over year, reflecting the impact of Covid-19 monitoring headwinds and the transition of its high-throughput customers to NovaSeq X.

Illumina (ILMN) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Illumina (ILMN) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Illumina (ILMN) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Illumina (ILMN) delivered earnings and revenue surprises of 300% and 2.42%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

EXEL or ILMN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

EXEL vs. ILMN: Which Stock Is the Better Value Option?

Tarsus Pharmaceuticals, Inc. (TARS) Soars 8.6%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Tarsus Pharmaceuticals, Inc. (TARS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Illumina (ILMN) Partners With Henry Ford Health for NGS Test

by Zacks Equity Research

Illumina (ILMN) collaborates with Henry Ford Health to conduct a series of studies that is likely to focus on the genetic drivers of cardiovascular disease.

Illumina (ILMN) to Expand Genomics Capacity With New Pact

by Zacks Equity Research

Illumina's (ILMN) recent collaboration is built on the shared goal of the organizations to expand sequencing capabilities and capacity for all people in Africa.

Illumina's (ILMN) NovaSeq X Exceeds 200 Order Milestone

by Zacks Equity Research

Illumina's (ILMN) NovaSeq X records the strongest pre-launch demand ever witnessed for any instrument.

Illumina (ILMN) to Enable Tertiary Analysis With New Launch

by Zacks Equity Research

Illumina's (ILMN) Connected Software is an end-to-end software system that standardizes analysis tools and connects data across the genomics workflow.

Why Is Seattle Genetics (SGEN) Up 24.6% Since Last Earnings Report?

by Zacks Equity Research

Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Illumina (ILMN) Unveils Complete Long Reads Technology

by Zacks Equity Research

Illumina's (ILMN) Complete Long Read Prep combines Illumina sequencing by synthesis chemistry with DRAGEN secondary analysis to provide WGS with more accuracy.

Company News for Mar 14, 2023

by Zacks Equity Research

Companies In The News Are: SGEN, PFE, PODD, SIVB, ILMN, PNC.

Rimmi Singhi headshot

Steer Clear Of These 4 Toxic Stocks to Avoid Losses

by Rimmi Singhi

Correctly spotting overpriced stocks and shunning them at the right time may avoid portfolio bleeding. ILMN, LTRX, BSY and CDMO are a few such toxic stocks.

Myriad Genetics' (MYGN) New Pact to Extend HRD Testing Access

by Zacks Equity Research

Myriad Genetics (MYGN), together with Illumina, will seek joint HRD companion diagnostics partnerships with pharmaceutical companies globally.

Illumina (ILMN) Q4 Earnings Miss Estimates, Gross Margin Down

by Zacks Equity Research

Delays in recruitment for some large research projects in the Americas and Europe, the impact of COVID disruptions in China and foreign exchange woes hurt Illumina's (ILMN) Q4 revenues.

Illumina (ILMN) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Illumina (ILMN) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Illumina (ILMN) Misses Q4 Earnings Estimates

by Zacks Equity Research

Illumina (ILMN) delivered earnings and revenue surprises of -26.32% and 1.54%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Illumina (ILMN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What's in the Cards for Illumina (ILMN) in Q4 Earnings?

by Zacks Equity Research

Negative foreign exchange impact and consumables inventory deleveraging are expected to have affected Illumina's (ILMN) top line during the fourth quarter.

Rimmi Singhi headshot

These 4 Toxic Stocks May Bring Bad Luck to Your Portfolio

by Rimmi Singhi

Consider dumping toxic stocks like BALY, OMCL, ILMN and AY from your portfolio to avoid huge losses.

Illumina (ILMN), Nashville Biosciences Partner With Amgen

by Zacks Equity Research

Illumina (ILMN) is currently keeping well with its goals to strengthen its foothold in the multi-billion gene sequencing market globally.

New Strong Sell Stocks for January 4th

by Zacks Equity Research

AVAH, CBRL and ILMN have been added to the Zacks Rank #5 (Strong Sell) List on January 4, 2023.

Rimmi Singhi headshot

5 Toxic Stocks That Can Set Off Alarm Bells for Your Portfolio

by Rimmi Singhi

Investors who can correctly spot overpriced stocks and shun them at the right time can avoid big losses. Dump toxic stocks like MGM, ILMN, OMCL, HL and RDNT to prevent portfolio bleeding.

Are Options Traders Betting on a Big Move in Illumina (ILMN) Stock?

by Zacks Equity Research

Investors need to pay close attention to Illumina (ILMN) stock based on the movements in the options market lately.